PF-08634404 (PD-1/VEGF Bispecific)

April 21, 2026 — Pfizer Inc. (NYSE: PFE) announced it will present new oncology data at the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, 2026, Chicago), spanning 40+ Pfizer-sponsored, investigator-sponsored, and collaborative abstracts, including three late-breaking sessions and eight oral/rapid oral presentations.

Key clinical updates include: a 7-year update from the Phase 3 CROWN study supporting LORBRENA (lorlatinib) as a guideline-recommended first-line therapy for ALK-positive metastatic NSCLC; late-breaking progression-free survival and overall survival data from Cohort 3 of the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) + cetuximab + FOLFIRI as first-line treatment for BRAF V600E–mutant metastatic colorectal cancer; and late-breaking Phase 3 TALAPRO-3 results showing clinically meaningful radiographic PFS benefit and a “strong OS trend” for TALZENNA (talazoparib) + XTANDI (enzalutamide) in HRR-altered metastatic castration-sensitive prostate cancer. Pfizer also highlighted HER2CLIMB-05 subgroup outcomes for TUKYSA (tucatinib) maintenance in HER2+ metastatic breast cancer and pipeline programs including PF-08634404 (PD-1/VEGF bispecific), sigvotatug vedotin (ADC), and atirmociclib (CDK4 inhibitor).

Business significance: strengthens Pfizer’s oncology portfolio positioning and advances multiple late-stage and next-generation assets that could shift standards of care and expand use into earlier treatment lines.